Ultragenyx Pharmaceutical Inc.’s EPS Growth at a glance
Ultragenyx Pharmaceutical Inc. reports eps growth of 23.8% for Dec 2024. The prior period recorded 18.5% (Dec 2023). Year over year the metric moved +5.3 pts (+28.6%). The rolling three-period average stands at -2.9%. Data last refreshed Dec 7, 2025, 2:53 AM.
Latest reading
23.8% · Dec 2024
YoY movement
+5.3 pts (+28.6%)
Rolling average
-2.9%
Current EPS Growth
23.8%
+5.3 pts
+28.6%
Rolling average
-2.9%
Latest Value
23.8%
Dec 2024
YoY Change
+5.3 pts
Absolute
YoY Change %
+28.6%
Rate of change
3-Period Avg
-2.9%
Smoothed
Narrative signal
Ultragenyx Pharmaceutical Inc.’s eps growth stands at 23.8% for Dec 2024. Year-over-year, the metric shifted by +5.3 pts, translating into a +28.6% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How eps growth shapes Ultragenyx Pharmaceutical Inc.'s story
As of Dec 2024, Ultragenyx Pharmaceutical Inc. reports eps growth of 23.8%. Review EPS trajectory, compounding pace, and earnings momentum supported by trailing annual filings.
Understanding EPS momentum
Sustained positive EPS growth underpins long-term shareholder returns. Volatility often reflects cyclical businesses or share-count changes.
Check the drivers behind EPS
Analyze revenue growth, margin expansion, and buybacks to see which levers are powering EPS gains.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
86.3%
Operating Margin
-95.7%
Net Profit Margin
-101.6%
Return on Equity
-222.9%
Return on Assets
-37.9%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Ultragenyx Pharmaceutical Inc. (RARE) FAQs
Answers tailored to Ultragenyx Pharmaceutical Inc.’s eps growth profile using the latest Financial Modeling Prep data.
What is Ultragenyx Pharmaceutical Inc.'s current eps growth?
As of Dec 2024, Ultragenyx Pharmaceutical Inc. reports eps growth of 23.8%. This reading reflects the latest filings and price data for RARE.
How is Ultragenyx Pharmaceutical Inc.'s eps growth trending year over year?
Year-over-year, the figure shifts by +5.3 pts (+28.6%). Pair this context with revenue growth and free cash flow signals to gauge momentum for RARE.
Why does eps growth matter for Ultragenyx Pharmaceutical Inc.?
Earnings-per-share growth reveals how quickly per-share net income is expanding or contracting versus the prior year. For Ultragenyx Pharmaceutical Inc., operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Ultragenyx Pharmaceutical Inc.'s eps growth above its recent average?
Ultragenyx Pharmaceutical Inc.'s rolling three-period average sits at -2.9%. Comparing the latest reading of 23.8% to that baseline highlights whether momentum is building or fading for RARE.
How frequently is Ultragenyx Pharmaceutical Inc.'s eps growth refreshed?
Data for RARE was last refreshed on Dec 7, 2025, 2:53 AM and updates automatically every 24 hours, keeping your valuation inputs current.